For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.
Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Sublocade (buprenorphine) from Indivior:Sublocade,
Licence. 350. Addex Therapeutics/ Indivior. ADX71441, selective positive allosteric modulator (PAM) for addiction (pc).
Indivior is on course to bring a new drug to market to tackle painkiller addiction in the US, offsetting the risks to its business from generic competition. ... An FDA advisory committee backed approval of Indivior’s RBP-6000 drug by a vote of eighteen
company launches ahead of the appeal outcome it would be at-risk of damages if Indivior's appeal is successful. ... RBP-6000 is due for an FDA verdict by November 30 and according to Indivior could have $1bn or more sales potential.
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...